More News! 25 Mar 2019 Swedish Biotech’s Stock Severely Hit by Failure of Biogen’s Alzheimer’s Drug …were scheduled to start a phase III trial of an antibody treatment for Alzheimer’s. Although the antibody is not the same as Biogen’s, both antibodies target pathological forms of a… March 25, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 1 Jul 2022 License submitted to FDA for drug to help those with large B-cell lymphoma A biologics license application has been submitted to the US Food and Drug Administration (FDA) for an antibody to treat patients with B-cell lymphoma. Genmab A/S is a biotechnology company… July 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 30 Oct 2017 Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014 …So what was the technology that Covagen developed that J&J took such an interest in? We started with the development of antibody alternatives, with Fynomers — small proteins of about… October 30, 2017 - 9 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 15 Jan 2018 British Biotech’s Technology is Taken by Pharma to Fight Alzheimer’s …candidates that originate from F-star’s development pipeline. Each drug has been developed for a specific genetically validated target and uses Denali’s Antibody Transport Vehicle (ATV) to help therapeutics across the… January 15, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 2 Apr 2020 Swiss and German Team to Develop Inhaled mRNA Coronavirus Treatment The Swiss antibody specialist Neurimmune and the German RNA biotech Ethris are collaborating to develop inhaled messenger RNA (mRNA) antibodies that can treat the catastrophic respiratory effects of coronavirus disease,… April 2, 2020 - 3 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2017 British Biotech Gets a £2.5M Grant to Boost Cancer Immunotherapy …the power’ of the immune system. One of its candidates is an antibody that targets the CD38 immune checkpoint, which is a marker of cell activation that is expressed by… November 14, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 20 Jul 2018 Belgian Biotech Completes First Trial with New Drug for Diabetic Macular Edema …the safety and tolerability of a new kind of antibody treatment for diabetic macular edema. The trial focused on injecting the THR-317 antibody, which is directed against the human placental… July 20, 2018 - 2 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 28 Jan 2019 Update: US District Court Rules Against MorphoSys’ Cancer Immunotherapy Patents …to CD38 for the treatment of cancer, including multiple myeloma. MOR202 induces antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) mediated killing of multiple myeloma cells. (Source: MorphoSys) With… January 28, 2019 - 3 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2018 Llama-Inspired Antibodies Succeed in Clinical Trials and Financial Deal Autoimmune disease and acute myeloid leukemia may have a llama-inspired antibody treatment one day. The Dutch company argenx’s antibodies have shown positive results in clinical trials, and have attracted Janssen… December 5, 2018 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jan 2017 An Antibody to reduce Hospitalizations of Children starts Phase IIb trials …JP Morgan this year, develops nanobodies derived from llamas. The Belgian company announced yesterday that its candidate ALX-0171 has entered testing in Phase IIb as a treatment for respiratory syncytial… January 12, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 Shooting for the Moon: German Biotech Acquired for a Record €1.3B …in Germany. Astellas will pay €442M upfront and is offering up to an extra €860M pending the successful development of Ganymed’s pipeline lead candidate, IMAB362. The therapeutic antibody has orphan… October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 15 May 2024 Drugs for IgA nephropathy on the rise in the clinic …the kidneys against placebo in a phase 3 trial. The study is set to end next year. Moreover, Boston-based Alexion Pharmaceuticals’ monoclonal antibody ALXN1210, also known as ravulizumab is currently… May 15, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email